Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.
Standard
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. / Engelhardt, Monika; Kleber, Martina; Udi, Josefina; Wäsch, Ralph; Spencer, Andrew; Patriarca, Francesca; Knop, Stefan; Bruno, Benedetto; Gramatzki, Martin; Morabito, Fortunato; Kropff, Martin; Neri, Antonino; Sezer, Orhan; Hajek, Rom; Bunjes, Donald; Boccadoro, Mario; Straka, Christian; Cavo, Michele; Polliack, Aaron; Einsele, Hermann; Palumbo, Antonio.
In: LEUKEMIA LYMPHOMA, Vol. 51, No. 8, 8, 2010, p. 1424-1443.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.
AU - Engelhardt, Monika
AU - Kleber, Martina
AU - Udi, Josefina
AU - Wäsch, Ralph
AU - Spencer, Andrew
AU - Patriarca, Francesca
AU - Knop, Stefan
AU - Bruno, Benedetto
AU - Gramatzki, Martin
AU - Morabito, Fortunato
AU - Kropff, Martin
AU - Neri, Antonino
AU - Sezer, Orhan
AU - Hajek, Rom
AU - Bunjes, Donald
AU - Boccadoro, Mario
AU - Straka, Christian
AU - Cavo, Michele
AU - Polliack, Aaron
AU - Einsele, Hermann
AU - Palumbo, Antonio
PY - 2010
Y1 - 2010
N2 - Treatment for multiple myeloma (MM) has changed beyond recognition over the past two decades. During the early 1980s, MM inevitably resulted in a slow progressive decline in quality of life until death after about 2 years, while today patients can expect a 50% chance of achieving a complete remission, median survival of 5 years, and a 20% chance of surviving longer than 10 years. An international expert opinion meeting (including members of the GIMEMA and DSMM study groups) was held in 2009. One of the outcomes of the meeting was the development of a consensus statement outlining contemporary optimal clinical practice for the treatment of MM. The international panel recommended that the state of the art therapy for MM should comprise: (a) evidence-based supportive care, (b) effective and well-tolerated chemotherapeutic regimens, (c) autologous hematopoietic stem cell transplant (ASCT) for patients suitable for intensive conditioning therapy, and (d) evidence-based incorporation of novel anti-MM agents. Maintenance strategies have also become increasingly important for the prolongation of remission after front-line therapies. In addition, improved understanding of the biology of MM has led to the development of novel biological therapeutic agents such as thalidomide, lenalidomide, bortezomib, and others. These agents specifically target intracellular mechanisms and interactions, such as those within the bone marrow microenvironment, and have been integrated into MM treatment. This report reviews recent clinical advances in the treatment strategies available for MM and provides an overview of the state of the art management of patients with MM.
AB - Treatment for multiple myeloma (MM) has changed beyond recognition over the past two decades. During the early 1980s, MM inevitably resulted in a slow progressive decline in quality of life until death after about 2 years, while today patients can expect a 50% chance of achieving a complete remission, median survival of 5 years, and a 20% chance of surviving longer than 10 years. An international expert opinion meeting (including members of the GIMEMA and DSMM study groups) was held in 2009. One of the outcomes of the meeting was the development of a consensus statement outlining contemporary optimal clinical practice for the treatment of MM. The international panel recommended that the state of the art therapy for MM should comprise: (a) evidence-based supportive care, (b) effective and well-tolerated chemotherapeutic regimens, (c) autologous hematopoietic stem cell transplant (ASCT) for patients suitable for intensive conditioning therapy, and (d) evidence-based incorporation of novel anti-MM agents. Maintenance strategies have also become increasingly important for the prolongation of remission after front-line therapies. In addition, improved understanding of the biology of MM has led to the development of novel biological therapeutic agents such as thalidomide, lenalidomide, bortezomib, and others. These agents specifically target intracellular mechanisms and interactions, such as those within the bone marrow microenvironment, and have been integrated into MM treatment. This report reviews recent clinical advances in the treatment strategies available for MM and provides an overview of the state of the art management of patients with MM.
KW - Humans
KW - Antineoplastic Agents therapeutic use
KW - Remission Induction
KW - Stem Cell Transplantation
KW - Consensus
KW - Multiple Myeloma diagnosis
KW - Practice Guidelines as Topic standards
KW - Humans
KW - Antineoplastic Agents therapeutic use
KW - Remission Induction
KW - Stem Cell Transplantation
KW - Consensus
KW - Multiple Myeloma diagnosis
KW - Practice Guidelines as Topic standards
M3 - SCORING: Zeitschriftenaufsatz
VL - 51
SP - 1424
EP - 1443
JO - LEUKEMIA LYMPHOMA
JF - LEUKEMIA LYMPHOMA
SN - 1042-8194
IS - 8
M1 - 8
ER -
